Open-Label Surufatinib in European Patients With NET
Status:
Recruiting
Trial end date:
2022-10-15
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to
intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).